Prevenar 20 is built on the foundation of PREVENAR 13 (Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)).¹⁰

Prevenar 20 helps protect against some of the most prevalent serotypes causing pneumococcal pneumonia in adults.^11,12

Polysaccharide vaccines elicit a T-cell independent response, which produces antibodies that are short-lived and cannot be boosted.^13-16

Conjugate vaccines, on the other hand, elicit a T-cell dependent response, resulting in higher affinity antibodies and provides long lasting protection compared to polysaccharide vaccines.^13-16

Prevenar 20, as a conjugate pneumococcal vaccine, induces serum antibody protection and immunologic memory against the 20 serotypes contained in the vaccine. By eliciting a T-cell-dependent response, it promotes the generation of memory B cells, which enable a strong booster response upon re-exposure to pneumococcal bacteria.^13-16

The information below is general vaccine information and not all information is specific to pneumococcal vaccines.

Prevenar 20 is indicated for active immunisation for the prevention of pneumococcal disease caused by Streptococcus pneumoniae in individuals from 6 weeks and older.⁴ Prevenar 20 should be used in accordance with official recommendations.

Given the elevated burden of pneumocccal disease in older adults and individuals with underlying clinical risk coniditons, the pneumococcal National Immunisation Programme targets these groups for pneumococcal vaccination.

Among adults aged ≥ 18 years hospitalised with pneumococcal lower respiratory infection in the UK, around 71% were 65 years and older and around 94% were at increased risk.¹¹

Individuals with clinical risk factors face elevated risk of pneumococcal disease compared to healthy adults.¹⁸

Those at clinical risk according to the Green Book include:³

• Chronic respiratory disease
• Chronic cardiovascular disease
• Diabetes
• Those with a suppressed immune system
• Chronic liver disease
• Chronic kidney disease
• Asplenia
• Individuals with cochlear implants
• Individuals with cerebrospinal fluid leaks
• Individuals at occupational risk

• Residents of care homes or other long-term care facilities^19-22
• Individuals who travel abroad to specific countries²³
• Smokers^24,25

One dose (0.5mL) of Prevenar 20 should be administered intramuscularly, preferably in the anterolateral aspect of the thigh (vastus lateralis muscle) in infants or the deltoid muscle of the upper arm in children and adults, with care to avoid injection into or near nerves and blood vessels.⁴

Prevenar 20 has a 24-month shelf life and should be stored in a refrigerator (2 C to 8 C). Do not freeze.⁴

Once removed from the refrigerator, Prevenar 20 should be used immediately.⁴


Refer to the Prevenar 20 Summary of Product Characteristics for more information.

Paedriatic population

In infants and children, 6 weeks to less than 5 years of age, Prevenar 20 can be administered concomitantly with any of the following vaccine antigens, either as monovalent or combination vaccines: diphtheria, tetanus, acellular pertussis, hepatitis B, Haemophilus influenzae type b, inactivated poliomyelitis, measles, mumps, rubella, and varicella vaccines. The vaccine has been safely administered with influenza and rotavirus vaccines.⁴

Individuals 18 years of age and older

Prevenar 20 can be administered concomitantly with seasonal influenza vaccine (surface antigen, inactivated, adjuvanted). In subjects with underlying conditions associated with a high risk of developing life-threatening pneumococcal disease, consideration may be given to separating administrations of seasonal influenza vaccine and Prevenar 20 (e.g., by approximately 4 weeks).⁴

In a double-blind, randomised study (B7471004) in adults 65 years of age and older, the immune response was formally non-inferior, however numerically lower titres were observed for all pneumococcal serotypes included in Prevenar 20 when given concomitantly with a quadrivalent seasonal influenza vaccine (surface antigen, inactivated, adjuvanted) compared to when Prevenar 20 was given alone. The clinical relevance of this finding is unknown.⁴

Prevenar 20 can be administered concomitantly with COVID-19 mRNA vaccine (nucleoside modified).

There are no data on the concomitant administration of Prevenar 20 with other vaccines.⁴

As Prevenar 20 contains the same 13 serotype-specific capsular polysaccharide conjugates and the same vaccine excipients as Prevenar 13, the adverse reactions already identified for Prevenar 13 have been adopted for Prevenar 20.⁴

Table 1 shows adverse reactions from clinical trials, based on the highest frequency reported after vaccination with Prevenar 20 or in the integrated dataset. Data for infants reflect Prevenar 20 given alongside routine childhood vaccines. For reactions seen in Prevenar 13 trials but not in Prevenar 20 trials, the frequency shown is from Prevenar 13.⁴

Prevenar 20’s safety profile was similar to Prevenar 13, with no new adverse reactions identified.

Adverse reactions are listed by system organ class in decreasing order of frequency and seriousness. Frequency definitions: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated).

Table 2 lists adverse events spontaneously reported during postmarketing use of Prevenar 13 in paediatric and adult populations, which may also occur with Prevenar 20. As Prevenar 20 contains all components of Prevenar 13, its postmarketing safety experience is relevant. These events were reported voluntarily from an unknown population size, so their frequency cannot be reliably estimated, nor can a causal relationship be confirmed for all events.⁴